Navigation Links
ActivBiotics Receives FDA Orphan Drug Designation for Superoxide Dismutase Mimetic, M40403, in Oral Mucositis of Cancer
Date:3/6/2008

WELLESLEY HILLS, Mass., March 6 /PRNewswire/ -- Joseph F. Finn, Jr., CPA, the Assignee for the Benefit of Creditors of ActivBiotics, announced today that the Office of Orphan Products Development of the Food and Drug Administration (FDA) has granted Orphan Drug Designation for M40403 for the prevention of radiation -- or chemotherapy -- induced oral mucositis (OM) in cancer patients.

The development of oral mucositis is a major, debilitating side-effect in the radiation and chemotherapy of cancer. Oral mucositis is one of the main reasons for poor compliance with and early discontinuation of therapy by patients being treated for their condition. Nearly half a million patients develop oral mucositis each year across all cancer indications, and of these 90% are associated with solid tumors. Although the estimated potential of the total oral mucositis market is $1- 2 billion, this therapeutic area is one of high unmet medical need, with few successful treatment options available.

By targeting various early stage inflammatory pathways implicated in the development of oral mucositis, M40403 may have particularly unique potential as a successful therapeutic in this disorder.

FDA's Orphan Drug Act was designed to encourage the development of products that demonstrate promise for the diagnosis, prevention and/or treatment of life-threatening or very serious conditions that are rare and affect not more than 200,000 persons in the United States. Orphan Drug Designation provides an important economic incentive for the development of new products in the cancer field. US Orphan Designation provides for 7 years of market exclusivity, reduction regulatory fees, and additional regulatory support for R&D initiatives.

About M40403

This investigational small molecule mimics the action of a natural component of the cells, an enzyme called superoxide dismutase. Superoxide dismutase is thought to have a double pharmacologic effect during the earl
'/>"/>

SOURCE ActivBiotics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. ActivBiotics Set to Sell Proprietary Assets, Including Drug Product Candidates, on March 14, 2008
2. ActivBiotics Completes Sale of Fixed Assets; Expands Due Diligence Initiative for the Sale of Intellectual Property, Including Drug Product Candidates
3. ActivBiotics Sells Proprietary Assets, Including Drug Product Candidates
4. New 300mg Loading Dose Tablet for Plavix(R) Receives Positive Opinion From the European Committee for Medicinal Products (CHMP)
5. Osteotech Receives FDA Clearance for Plexur M(TM) Biocomposite
6. Ventria Receives Friends of Education Award From Geary County School District
7. STAAR Surgical Receives Approval to Market Visian(R) Toric Implantable Collamer Lens in China
8. Actavis Receives Approval for Irinotecan Hydrochloride Injection; Extends US Portfolio with First Injectable Product
9. Kyowa Hakko Receives Not Approvable Letter from FDA for Istradefylline (KW-6002)
10. Vermillion Receives NASDAQ Notice of Non-Compliance
11. Purchase Agreement for Antibody Manufacturing Facility Receives Antitrust Clearance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... 2013 The Pistoia Alliance ... HELM biomolecular representation standard software toolkit and editor ... HELM (Hierarchical Editing Language for Macromolecules) enables ... (e.g. proteins, nucleotides, antibody drug conjugates) whose size ... methodologies impractical or unusable. HELM solves this problem ...
(Date:6/18/2013)... 18, 2013  AMRI (NASDAQ: AMRI ... Mass. , site has received approval to ... registration to handle Schedule 2 and 2N controlled ... Burlington,s physical security and ... (Logo: http://photos.prnewswire.com/prnh/20120229/NY61160LOGO ) ...
(Date:6/18/2013)... June 18, 2013  Techne Corporation (NASDAQ: ... has agreed to acquire 100% ownership of Bionostics ... (Bionostics).  Bionostics is a global leader in the ... verify the proper operation of in vitro ... of care blood glucose and blood gas testing.  ...
(Date:6/18/2013)... DUBLIN , June 18, 2013 /PRNewswire/ ... http://www.researchandmarkets.com/research/4b8vj2/injectable_drug ) has announced the addition of ... Formulations [Liposomes, Microspheres, & Nanoparticles], Devices [Disposables ... Free & Auto Injectors] & Therapeutics [Diabetes ... report to their offering. ...
Breaking Biology Technology:The Pistoia Alliance Releases HELM Biomolecular Representation Standard Open Source Tools 2AMRI Burlington Receives DEA Approval to Handle Controlled Substances 2Techne Corporation Announces Acquisition Agreement 2Techne Corporation Announces Acquisition Agreement 3Techne Corporation Announces Acquisition Agreement 4Techne Corporation Announces Acquisition Agreement 5Injectable Drug Delivery Market by Formulations, Devices & Therapeutics - Global Forecasts to 2017 2Injectable Drug Delivery Market by Formulations, Devices & Therapeutics - Global Forecasts to 2017 3
... provider Merge eFilm announced it will change its ... on June 1 with Cedara Software and eMed ... headquartered in Milwaukee and will be divided into ... systems and picture archiving communication systems, and Cedara ...
... use of clinical technologies in healthcare does not absolve ... decisions, particularly when technology vendors include strong sales contract ... their products more directly to consumers, they will assume ... the recent Digital Healthcare Conference in Madison ...
... Small Tree Communications , a supplier of high-performance networking ... software protocol called Blaze, expected to ship in the third ... High-Definition digital video editing. , ,Blaze will make it ... on the newer high-end 10 gigabit Ethernet cards. It ...
Cached Biology Technology:Liability issues not seen as roadblock to healthcare technology advancements 2Liability issues not seen as roadblock to healthcare technology advancements 3Small Tree is streamlining digital video editing 2Small Tree is streamlining digital video editing 3
(Date:6/18/2013)... the Energy Department,s National Renewable Energy Laboratory (NREL), ... a paper describing a novel cellulose-degrading enzyme from ... commonly known as the gribble. , Gribbles ... unique ability to produce their own enzymes instead ... biomass they eat. New biomass-degrading enzymes from novel ...
(Date:6/18/2013)... Marc Torrent, Ph.D., Medical Research Council, Laboratory of ... of a 2013 ICAAC Young Investigator Award. Torrent ... includes developing the first algorithm to predict antimicrobial ... Biolgicas(CSIC), said, "we are now applying this algorithm ... new antimicrobial peptide leads with very appealing results." ...
(Date:6/18/2013)... herbal extract of a yellow-flowered mountain plant long used ... of fruit fly populations by an average of 24 ... how Rhodiola rosea , also known ... of study leaders Mahtab Jafari and Sam Schriner. They ... completely unrelated to dietary restriction and affects different molecular ...
Breaking Biology News(10 mins):Novel enzyme from tiny gribble could prove a boon for biofuels research 2The American Society for Microbiology honors Marc Torrent 2Herbal extract boosts fruit fly lifespan by nearly 25 percent, UCI study finds 2
... team of experts in biomechanics and physiology from ... the Massachusetts Institute of Technologys Media Lab, refute ... Pistorius, a 21-year-old South African bilateral amputee track ... the 400-meter race. Their conclusions were based on ...
... State researchers has developed a simple artificial cell with which ... most basic cell components: the cell membrane and the cytoplasm--the ... The work could lead to the creation of new drugs ... the development of diseases. The team,s findings will be ...
... power output of one type of fuel cell ... could help these environmentally friendly energy storage devices ... electronics. The new material key to the ... conventional industrial counterpart, among other advantages. Our ...
Cached Biology News:Breaking news: Study revives Olympic prospects for amputee sprinter 2Breaking news: Study revives Olympic prospects for amputee sprinter 3Simple model cell is key to understanding cell complexity 2MIT creates new material for fuel cells 2MIT creates new material for fuel cells 3
...
Mouse monoclonal antibody raised against a partial recombinant VEGFB. NCBI Entrez Gene ID = VEGFB...
... The Infinite 200 series of microplate readers ... absorbance detection in an affordable, easy-to-use platform ... applications. The unique modular design and adaptability ... with a choice of a monochromator (M200) ...
...
Biology Products: